Ursula M Vogl
Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Çakar E, Oniangue-Ndza C, Schneider R, Klijn S, Vogl U, Rothermundt C, May J. Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. Pharmacoecon Open 2023
Feb 9, 2023Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.
Feb 9, 2023Pharmacoecon Open 2023
Çakar Esra, Oniangue-Ndza César, Schneider Ralph P, Klijn Sven L, Vogl Ursula M, Rothermundt Christian, May Jessica R
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Vogl U, Mottet N, Padhani A, Roach M, Rubin M, Sartor O, Small E, Smith M, Soule H, Sydes M, Tombal B, Omlin A, Gillessen S, James N, Halabi S, Beer T, Davis I, Shore N, Sweeney C, Ost P, Attard G, Bossi A, de Bono J, Drake C, Efstathiou E, Fanti S, Fizazi K, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer 2021; 160:24-60.
Nov 26, 2021Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Nov 26, 2021Eur J Cancer 2021; 160:24-60
Vogl Ursula M, Mottet Nicolas, Padhani Anwar R, Roach Mack, Rubin Mark, Sartor Oliver, Small Eric, Smith Matthew R, Soule Howard, Sydes Matthew R, Tombal Bertrand, Omlin Aurelius, Gillessen Silke, James Nicolas, Halabi Susan, Beer Tomasz M, Davis Ian D, Shore Neal D, Sweeney Christopher J, Ost Piet, Attard Gerhardt, Bossi Alberto, de Bono Johann, Drake Charles G, Efstathiou Eleni, Fanti Stefano, Fizazi Karim, APCCC 2019 expert panel